Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nilofabicin - CrystalGenomics

Next Previous
Drug Profile

Nilofabicin - CrystalGenomics

Alternative Names: CG-400549; CG-549; Enoyl reductase inhibitors - CrystalGenomics; ERCG 0549; FabI inhibitor (CG400549) - CrystalGenomics

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CrystalGenomics
  • Class Amines; Antibacterials; Pyridines; Pyridones; Small molecules; Thiophenes
  • Mechanism of Action Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bacterial infections

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections
  • No development reported Staphylococcal infections; Vancomycin-resistant Staphylococcus aureus infections

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in Netherlands (PO, Tablet)
  • 30 Jun 2020 CrystalGenomics completes a phase-I clinical trial in Methicillin-resistant Staphylococcus aureus infections (In volunteers) in Netherlands (PO, Tablet) (NCT05393856)
  • 23 Sep 2019 Phase-I clinical trials in Methicillin-resistant Staphylococcus aureus infections (In volunteers) in Netherlands (PO, Tablet) (NCT05393856)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top